St. Jude Medical Advances Integration of Electrophysiology Lab Equipment with Launch of Several New Technologies
December 08 2010 - 8:00AM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced several new products that provide
physicians and hospitals with the opportunity for improved
efficiency and information connectivity in the electrophysiology
(EP) lab. The EnSite Connect™ Remote Support feature, EnSite
Courier™ Module, EnSite Velocity v2.0™ Software and recently
launched EnSite Derexi™ Module are advanced technologies that allow
a streamlined workflow within the EP lab.
Millions of people worldwide are affected by abnormal heart
rhythms, creating an ongoing need for diagnostic mapping and
ablative technologies. The new product offerings from St. Jude
Medical allow for a simplified diagnostic and treatment process,
added safety and the potential for reduced treatment time for the
patient.
“Improving procedural workflow is an important way to help
improve efficiency and manage the cost of delivering care,” said
Jane J. Song, president of the St. Jude Medical Atrial Fibrillation
Division. “Our streamlined EP Lab offerings provide advanced
technologies that optimize interconnectedness and continue to move
St. Jude Medical toward our ultimate goal of providing hospitals
with fully integrated and networked EP labs.”
About the EnSite Products
- EnSite Velocity v.2.0 Software – EnSite
Velocity v.2.0 Software adds new features and enhanced performance
to the EnSite Velocity System, which launched in 2009. The EnSite
Velocity v.2.0 is designed to help physicians more efficiently
diagnose and guide therapy to treat abnormal heart rhythms.
- EnSite Connect Remote Support – EnSite
Connect remote support improves lab efficiency by providing live,
real-time viewing of the EnSite Velocity System screen by
knowledgeable support staff. Through the use of a secure Internet
connection, EnSite Connect support allows for rapid
troubleshooting, system diagnosis and resolution of technical
issues, eliminating the need for electrophysiologists to download
and save case logs for off-site analysis.
- EnSite Courier Module – The EnSite
Courier Module seamlessly imports cardiac information and provides
efficient networking of cardiac images such as MR, CT and 3-D
rotational angiography. This networking software provides more
control for the EP lab to efficiently obtain cardiac datasets when
and where electrophysiologists need them.
- EnSite Derexi Module – The recently
launched EnSite Derexi™ Module contributes to the overall
connectivity of the EP lab by providing improved efficiency and
workflow, enabling communication between the EnSite™ Velocity™
Cardiac Mapping System and the EP-Workmate™ Recording System.
“The complete suite of St. Jude Medical EnSite Velocity System
products allow me to more easily collect and combine very detailed
anatomical and mapping data when diagnosing or treating
arrhythmias,” said Dr. William Nesbitt, of Texas Health Arlington
Memorial Hospital. “Compared to other systems, the user interface
is very intuitive and the ease of use with such a connected system
creates a more flexible, efficient environment for the entire EP
team.”
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting more control into the hands of those who treat
cardiac, neurological and chronic pain patients worldwide. The
company is dedicated to advancing the practice of medicine by
reducing risk wherever possible and contributing to successful
outcomes for every patient. St. Jude Medical is headquartered in
St. Paul, Minn. and has four major focus areas that include:
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Quarterly Report on Form 10-Q for the fiscal quarter
ended October 2, 2010. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
SJM (NYSE:STJ)
Historical Stock Chart
From Sep 2024 to Oct 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Oct 2023 to Oct 2024